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Abstract
Object In the past decade, the endonasal transsphenoidal ap-
proach (eTSA) has become an alternative to the microsurgical
transcranial approach (mTCA) for tuberculum sellae menin-
giomas (TSMs) and olfactory groove meningiomas (OGMs).
The aim of this meta-analysis was to evaluate which approach
offered the best surgical outcomes.
Methods A systematic review of the literature from 2004
and meta-analysis were conducted in accordance with
the PRISMA guidelines. Pooled incidence was calculat-
ed for gross total resection (GTR), visual improvement,
cerebrospinal fluid (CSF) leak, intraoperative arterial in-
jury, and mortality, comparing eTSA and mTCA, with
p-interaction values.
Results Of 1684 studies, 64 case series were included in the
meta-analysis. Using the fixed-effects model, the GTR rate
was significantly higher among mTCA patients for OGM
(eTSA: 70.9% vs. mTCA: 88.5%, p-interaction < 0.01), but
not significantly higher for TSM (eTSA: 83.0% vs. mTCA:
85.8%, p-interaction = 0.34). Despite considerable heteroge-
neity, visual improvement was higher for eTSA than mTCA
for TSM (p-interaction < 0.01), but not for OGM (p-interac-
tion = 0.33). CSF leak was significantly higher among eTSA
patients for both OGM (eTSA: 25.1% vs. mTCA: 10.5%, p-
interaction < 0.01) and TSM (eTSA: 19.3%, vs. mTCA:
5.81%, p-interaction < 0.01). Intraoperative arterial injury
was higher among eTSA (4.89%) than mTCA patients
(1.86%) for TSM (p-interaction = 0.03), but not for OGM
resection (p-interaction = 0.10). Mortality was not significant-
ly different between eTSA and mTCA patients for both TSM
(p-interaction = 0.14) and OGM resection (p-interac-
tion = 0.88). Random-effect models yielded similar results.
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Conclusion In this meta-analysis, eTSAwas not shown to be
superior to mTCA for resection of both OGMs and TSMs.
Keywords Endoscopic transsphenoidalsurgery .Microscopic
transcranial surgery . Tuberculum sellaemeningioma .
Olfactory groovemeningioma . Gross total resection .
Complications .Meta-analysis
Introduction
The mainstay of treatment for tuberculum sellae meningiomas
(TSMs) and olfactory groove meningiomas (OGMs) is sur-
gery. Goals of surgery include obtaining tissue for histopath-
ological diagnosis and relieving pressure caused by the tumor
on neighboring structures such as the olfactory nerves, anteri-
or cerebral arteries, optic nerves, and pituitary gland. At the
same time, these structures are very susceptible to manipula-
tion, and damage to these structures can lead to great morbid-
ity [51].
Traditionally, TSMs and OGMs are resected using a micro-
scopic transcranial approach (mTCA). Various approaches
have been described, including interhemispheric, pterional,
bifrontal, and subfrontal mTCA [1, 2, 5–7, 9, 47, 51, 56, 64,
70]. In the last decade, however, as a result of the evolution of
endoscopic surgery for pituitary adenomas, these meningio-
mas have been increasingly resected using an endonasal en-
doscopic transsphenoidal approach (eTSA), as first described
by Jho et al. in 2004 [38]. Although the endoscopic approach
is generally viewed as less invasive, with some studies sug-
gesting that eTSA caused fewer postoperative changes on
magnetic resonance imaging (MRI) compared to mTCA pos-
sibly indicating less manipulation [22], it has been suggested
that eTSA results in higher rates of CSF leaks and potentially
different outcomes (e.g., less GTR) [18, 42]. However, a direct
comparison between eTSA and mTCA is currently lacking.
Therefore, the aim of this systematic review and meta-analysis
was to evaluate which approach (eTSA vs. mTCA) offers the
best surgical outcomes.
Search strategy and paper selection
To identify studies reporting on outcomes of surgically treated
TSMs and OGMs, a systematic review of the literature was
conducted in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
Statement [54]. Both PubMed and Embase databases were
searched on September 12, 2016. Because the outcomes of
endoscopic surgery were first described in 2004 and micro-
scopic resection has seen a continuous improvement, only
articles published in 2004 or later were included [26, 38].
The search strategy was drawn up using the keywords
Bmeningioma,^ Btuberculum sellae,^ Bolfactory groove,^
and synonyms (Supplementary Table 1). Duplicates were re-
moved using Endnote X7.5.
Two authors (IM and TO) independently screened the titles
and abstracts of the articles for papers reporting surgical out-
comes of resected OGMs and TSMs. After full-text screening,
articles that reported outcomes of surgically treated OGMs
and TSMs were included. Case reports, commentaries, con-
gress abstracts, reviews, animal studies, studies describing an
endoscopically assisted approach, studies reporting on the use
of a keyhole approach, studies in pediatric patients (< 18 years
old), re-operations, and cadaveric studies were excluded. Only
literature in English and Dutch was reviewed. Discrepancies
in selection were sorted out by discussion, and a senior author
(MB) was consulted if the discrepancy could not be solved by
discussion.
Data extraction
The following study characteristics were extracted from the
full text of the selected studies: study design, number of pa-
tients, follow-up duration, study geographic location, percent-
age of WHO II and III meningiomas, percentage of males in
the study population, mean age of the study population, and
surgery type (transcranial or endoscopic endonasal). The fol-
lowing outcomes were extracted: number of patients with
GTR (defined as Simpson grade I or II), number of patients
with preoperative visual problems, number of patients with
improved vision post-surgery, postoperative cerebrospinal flu-
id (CSF) leakage, number of intraoperative arterial injury, and
all-cause mortality (within 30 days after resection).
Furthermore, perioperative blood loss, hospital length of stay,
and operation length were extracted. Study quality was
assessed with the adjusted Newcastle Ottawa Scale (NOS)
[80]. If the study in question was a case series, comparability
was ignored.
Meta-analysis
Comprehensive meta-analysis (CMA) version 3 was used to
calculate the separate overall incidence using the fixed-effect
model with the inverse variancemethod and the random-effect
model according to the method of DerSimonian and Laird
[27] in the endonasal endoscopic and transcranial approach
for the following variables: GTR, arterial injury, visual im-
provement, CSF leakage, and mortality. A resulting p-
interaction value from the subgroup analysis comparing
eTSA and mTCAwas considered significant if <0.05. Study
heterogeneity was assessed by calculating I-squared and P-
values from the Cochrane Q test. Publication bias was
assessed with Begg’s tests and was corrected for by a trim-
and-fill method. Finally, a meta-regression was conducted on
each of age, gender (dichotomized by male percentage below/
above the median category), and continent (North America as
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the reference) for eTSA and mTCA separately. For visual
outcomes, only continent could be assessed as a source of
heterogeneity as not all patients presented with visual prob-
lems and baseline characteristics from this subgroup were not
available. A subgroup analysis for tumor size and grade was
not possible because of great variance in reporting.
Results
After removing duplicates, 1684 articles were identified. After
screening for titles and abstracts, 1426 articles were excluded
and 216 full texts were reviewed (Fig. 1). For TSM, 44 case
series (of which 11 were in eTSA, 29 in mTCA, and 4 in both)
were included in the meta-analysis for the different outcomes,
including a total of 1444 patients [3, 5, 8, 11–13, 15, 16, 20,
21, 23, 25, 29, 30, 32, 34–36, 40, 41, 43, 45, 47–53, 56, 58,
61–63, 65, 66, 68, 69, 72, 73, 77, 79, 81, 82]. As for OGM, 25
case series (of which 6 were in eTSA, 18 in mTCA, and 1 in
both) were included describing outcomes in 891 patients [2, 4,
6, 7, 17, 19, 22, 24, 25, 35, 37, 40, 44, 47, 55, 57, 60, 62, 64,
67, 68, 70, 75, 76, 78].
The median number of patients per study was 24 for TSM
(Table 1) and 29 for OGM (Table 2). The average percentage
of male patients was 27% for TSM and 32% for OGM. The
median age was 51.0 for TSM and 52.0 for OGM. Themedian
follow-up time was 6.0 years based on 35 studies for TSM [3,
5, 8, 12, 13, 15, 16, 21, 25, 29, 30, 32, 34, 36, 43, 45, 47–53,
56, 61, 62, 65, 66, 68, 72, 73, 77, 79, 81, 82] and 7.0 years
based on 20 studies for OGM [2, 4, 6, 7, 17, 19, 22, 24, 25, 37,
44, 47, 55, 57, 60, 62, 67, 68, 76, 78]. The modified NOS
score varied between three and four of seven among the TSM
and OGM case series [3, 5, 8, 11–13, 15, 16, 20, 21, 23, 25,
29, 30, 32, 34–36, 40, 41, 43, 45, 47–53, 56, 58, 61–63, 65,
66, 68, 69, 72, 73, 77, 79, 81, 82]. Outcomes of the meta-
analysis for TSM (Table 3) and OGM (Table 4) are shown.
Gross total resection
For TSM, GTR after eTSA was reported in 14 studies [8,
11–13, 16, 20, 23, 29, 30, 40, 43, 61, 62, 79] and after
mTCA was reported in 31 studies [3, 5, 11, 13, 15, 21, 23,
25, 29, 32, 34, 36, 45, 47–49, 51–53, 56, 58, 63, 65, 66, 68,
69, 72, 77, 79, 81, 82]. In a fixed effect model, the overall
incidence for GTR was not significantly different comparing
eTSA (incidence = 83.0%; 95% CI = 76.7–88.0%, p-hetero-
geneity = 0.74, I2 = 0%, 221 patients) to mTCA (inci-
dence=85.8%(95%CI=83.6–87.9%,p-heterogeneity=0.07,
I2: 28.4%, 1223 patients) (p-interaction value = 0.34). In meta-
regression, TSM studies with lower percentage of males had a
higher rate of GTR (p = 0.03). Studies conducted in Europe
and Africa had significantly higher rates of GTR than those in
North America (p = 0.02). Begg’s test for publication bias was
non-significant (p = 0.31) (Table 3).
For OGM, GTR was specifically addressed in 7 eTSA [4,
22, 24, 35, 40, 44, 62] studies and 18 mTCA studies [2, 6, 7,
17, 19, 22, 25, 37, 47, 55, 57, 60, 64, 67, 68, 70, 75, 76].
Unlike TSM, the overall fixed incidence of GTR was signif-
icantly lower in eTSA (incidence = 70.9%; 95% CI = 60.3–
79.9%, p-heterogeneity = 0.45, I2 = 0%, 86 patients) com-
pared to mTCA (88.5%; 95% CI = 85.9–90.7%, p-heteroge-
neity = 0.06, I2:36.5%, 786 patients) (p-interaction < 0.01;
Fig. 2). In meta-regression, only higher age was associated
with lower GTR in resected OGM with the eTSA approach
with borderline significance (p = 0.05). Begg’s test for publi-
cation bias was non-significant (p = 0.48) (Table 4).
Visual improvement
Visual outcomes were reported in 12 studies for eTSA [8, 12,
16, 23, 29, 30, 35, 40, 43, 61, 62, 79] and 28 studies for mTCA
[3, 5, 13, 15, 21, 23, 25, 29, 32, 34, 36, 47–51, 56, 63, 65, 66,
68, 69, 72, 73, 77, 81, 82] with a total of 1139 patients pre-
senting with visual problems [3, 5, 8, 12, 13, 15, 16, 21, 23,
25, 29, 30, 32, 34–36, 40, 43, 47–51, 53, 56, 61–63, 65, 66,
68, 69, 72, 73, 77, 79, 81, 82]. Postoperative visual improve-
ment was significantly higher for eTSA (incidence = 77.7%;
95% CI = 70.3–83.7%, p-heterogeneity = 0.37, I2 = 7.90%,
167 patients) than mTCA (incidence = 60.7%; 95%
CI = 57.3–64.0, p-heterogeneity < 0.01, I2 = 77.4%, 1139
patients) in fixed-effect models (p-interaction < 0.01).
Because age and male percentage were not provided for this
subgroup of patients who presented with visual problems,
only continent could be assessed as a source of heterogeneity,
which was not a significant source of heterogeneity for TSM
resection using eTSA or MTCA. Begg’s test for publication
bias was non-significant (p = 0.14) (Table 3). One study spe-
cifically addressed visual improvement per approach in TSM
resection, finding that eTSAwas associated with more visual
acuity improvement (≥5%; p-value: 0.01), but not with im-
provement of visual field deficits (p-value = 0.61) [41].
Visual improvement in OGM patients was described four
eTSA studies [4, 40, 44, 62] and nine mTCA studies [6, 7, 47,
57, 60, 68, 70, 75, 78] with 224 patients presenting with visual
symptoms. The resulting fixed overall improvement rate was
64.5% (95% CI: 37.9–84.4%, p-heterogeneity = 0.03;
I2 = 65.5%) for eTSA compared to 50.6% (95% CI = 42.9–
58.4%, p-heterogeneity <0.01, I2 = 68.6%) for mTCA; how-
ever, this difference was not significant (p-interaction value:
0.33). Continent was not identified as a significant source of
heterogeneity for eTSA (p = 0.34) and mTCA (p = 0.57).
Begg’s test for publication bias was non-significant
(p = 0.25) (Table 4).
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Cerebrospinal fluid leakage
CSF leak occurrence after TSM resection was extracted from
15 eTSA studies [8, 11, 16, 20, 23, 29, 30, 35, 40, 43, 61, 62,
79, 81] and 24 mTCA studies. The overall incidence of post-
operative CSF leakage was significantly higher in patients
treated with the eTSA approach (incidence = 19.3%; 95%
CI = 14.1–25.8%, p-heterogeneity = 0.50, I2 = 0%, 225 pa-
tients) than with mTSA (incidence = 5.81%; 95% CI = 4.33–
7.75%, p-heterogeneity = 0.93, I2 = 0%, 879 patients) in fixed
models (p-interaction value <0.01, Fig. 3a). Age, gender, and
continent were not identified as sources of heterogeneity using
meta-regression (all p-value > 0.05). Begg’s test revealed no
significant publication bias (p = 0.98) (Table 3).
In OGM, 7 eTSA studies [4, 22, 24, 35, 40, 44, 62] and 17
mTCA studies [2, 6, 7, 17, 19, 22, 25, 37, 55, 57, 60, 64, 67,
68, 70, 75, 76, 78] including 889 patients described whether
patients developed a CSF leak postoperatively. The overall
incidence in fixed models was statistically significantly higher
(p-interaction < 0.01) for eTSA (incidence = 25.1%; 95%
CI = 17.5–34.8%, p-heterogeneity = 0.22, I2 = 25.8%) than
mTCA (incidence = 10.5%; 95% CI = 8.22–13.4%, p-
heterogeneity <0.01, I2 = 60.2%) (Fig. 3b). In meta-regres-
sion, only older age was significantly associated with a lower
CSF leakage rate for mTCA (p < 0.01). For eTSA, age, gen-
der, and continent were not identified as potential effect mod-
ifiers (p-interaction for all > 0.05). Begg’s test indicated no
significant publication bias (p = 0.30) (Table 4).
Intraoperative arterial injury
For intraoperative arterial injury, outcomes were extracted
from 12 eTSA studies [8, 11, 16, 23, 29, 30, 35, 40, 43, 61,
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62, 79] and 27 mTCA studies for TSM [3, 5, 11, 12, 15, 21,
23, 25, 29, 32, 36, 45, 48, 49, 51, 52, 56, 58, 63, 65, 68, 69, 72,
77, 81, 82]. The overall incidence of intraoperative arterial
injury was significantly higher for eTSA (incidence = 4.89%;
95% CI = 2.33–9.94%, p-heterogeneity = 0.97, I2 = 0%, 225
patients) than for MTCA (incidence = 1.86%; 95% CI = 1.13–
3.05%, p-heterogeneity = 0.99, I2 = 0%, 225 patients) in fixed
effect models (p-interaction value = 0.03; Fig. 4). Trial-level
covariates such as age, continent, and gender did not signifi-
cantly contribute to any heterogeneity in the models for both
eTSA and mTCA (all p-interaction values > 0.05). There was
a significant publication bias, indicating that study results with
higher arterial injury incidence tended not to be published
(Begg’s test p-value < 0.01) (Table 3). However, the imputed
overall incidence estimate for TSM was not materially differ-
ent from the original incidence rate (not shown).
For OGM, the incidence of intraoperative arterial injury
was extracted from 858 patients in 7 eTSA studies [4, 22,
24, 35, 44, 62] and 17 mTCA studies [2, 6, 7, 17, 19, 22,
25, 37, 55, 57, 60, 64, 67, 68, 70, 75, 76, 78]. For eTSA, the
fixed overall incidence of intraoperative arterial injury was
3.88% (95% CI = 1.55–9.43%, p-heterogeneity = 0.98,
I2 = 0%). Although lower, the incidence for mTCA was
1.62% (95% CI = 0.87–2.98%, p-heterogeneity = 0.99,
I2 = 0%) but not significantly different (p-interaction = 0.12).
Covariates such as age, gender, and continent were not iden-
tified as sources of heterogeneity for both eTSa and mTCA
procedures (all p-interaction > 0.05). Although Begg’s test for
publication bias indicated the presence of publication bias (p-
value < 0.01), Egger’s test did not (p-value = 0.50) (Table 4).
Moreover, the imputed overall incidence estimates for OGM
were not materially different from the original incidence
values (not shown).
Mortality
Mortality after TSM surgery was described in a total of 10
eTSA studies [8, 11, 23, 29, 40, 43, 61, 62, 79] and 30 mTCA
studies [3, 5, 11–13, 15, 21, 23, 25, 29, 30, 35, 36, 45, 48, 49,
51–53, 56, 58, 63, 65, 68, 69, 72, 77, 81, 82]. eTSA resulted in
a 30-day mortality incidence of 5.15% (95% CI = 2.39–10.8,
p-heterogeneity = 0.85, I2 = 0%, 194 patients), which was not
significantly different from mTCA (incidence = 2.67%; 95%
CI = 1.77–4.02, p-heterogeneity = 0.99, I2 = 0%, 962 patients)
in fixed models (p-interaction = 0.14). Age, gender, and con-
tinent did not appear to have different incidence values based
on the meta-regression results for both eTSA and mTCA (all
Model Group by
SURGERY
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
eTSA Banu et al.E 0.50 0.17 0.83
eTSA De Almeida et al.E 0.70 0.38 0.90
eTSA De Devitiis et al.E 0.90 0.33 0.99
eTSA Hayhurst et al.E 0.94 0.50 1.00
eTSA Khan et al.E 0.82 0.49 0.95
eTSA Koutourousiou et al.E 0.67 0.52 0.79
eTSA Padhyeet al.E 0.88 0.46 0.98
0.800.600.71eTSAFixed
0.830.590.73eTSARandom
mTCA Aguiar et al. 0.98 0.72 1.00
mTCA Bassiouni et al. 0.90 0.80 0.96
mTCA Bitter et al. 0.98 0.89 1.00
mTCA Ciurea et  al. 0.88 0.77 0.94
mTCA Colliet al. 0.94 0.68 0.99
mTCA De Almeida et al. 0.90 0.53 0.99
mTCA Della Puppa et al. 0.98 0.71 1.00
mTCA Jang et al. 0.93 0.79 0.98
mTCA Leveque et al. 0.91 0.76 0.97
mTCA Mukherjee et al. 0.85 0.68 0.94
mTCA Nakamura et al. 0.93 0.85 0.97
mTCA Nanda et al. 0.91 0.81 0.96
mTCA Pallini et al. 0.84 0.76 0.90
mTCA Pepper et al. 0.63 0.40 0.81
mTCA Refaat etal. 0.79 0.51 0.93
mTCA Romani et al. 0.91 0.81 0.96
mTCA Slavik et al. 0.98 0.78 1.00
mTCA Spektor et al. 0.90 0.81 0.95
0.910.860.88mTCAFixed
0.920.860.89mTCARandom
0.880.830.86OverallFixed
0.900.830.87OverallRandom
-1.00 -0.50 0.00 0.50 1.00
Fig. 2 Pooled prevalence of gross total resection by approach for olfactory groove meningioma resection: endoscopic transsphenoidal approach vs.
microscopic transcranial approach. P-interaction value < 0.01. eTSA, endoscopic transsphenoidal approach; mTCA, microscopic transcranial approach
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p > 0.05). Begg’s test p-value for publication bias was signif-
icant, indicating that articles with higher mortality rates tend
not to be published (p < 0.01) (Table 3); however, the trim-
and-fill method suggested that the imputed overall incidence
estimates for TSMwere not materially different from the orig-
inal incidence values (not shown).
For OGM, 7 eTSA studies [4, 22, 24, 35, 40, 44, 62] and 19
mTCA studies [2, 6, 7, 17, 19, 22, 25, 37, 47, 55, 57, 60, 64,
67, 68, 70, 75, 76, 78] including described mortality inci-
dence. For eTSA, the overall 30-day mortality incidence was
4.27% (95% CI = 1.50–11.6%, p-heterogeneity = 0.94;
I2 = 0%; 82 patients), which was not significantly different
from the mortality incidence in the mTCA group (inci-
dence = 3.92%, 95% CI = 2.66–5.75, p-heterogeneity = 0.74,
I2 = 0%; 779 patients) in fixed models (p-interaction = 0.88).
In a meta-regression for gender, it was identified that studies
with a lower male percentage were significantly associated
with a higher mortality incidence for mTCA (p = 0.02) but
not for eTSA (p = 0.34), while age and continent were not.
Begg’s test for publication bias was non-significant (p = 0.21)
(Table 4).
Random-effect models
For all the above-mentioned results, the random-effect models
yielded similar results (Tables 3 and 4).
Blood loss, operating time, and length of stay
in hospital
For blood loss, operating time, and length of hospital stay, a
quantitative meta-analysis was not feasible because of the
paucity of studies reporting them; hence, these few studies
were systematically reviewed. In TSM, mean blood loss
ranged from 448 to 970 ml in three studies describing
mTCA compared to 200 to 617 ml for eTSA [21, 30, 41,
47]. The mean operating time ranged from 375 to 444 min
for eTSA in two studies and from 116 to 426min for mTCA in
four studies [21, 23, 41, 47, 69]. Hospital length of stay ranged
from 6 to 21 days in one study in patients treated by an eTSA
[23].
For OGM, blood loss was only reported in one case series
in patients operated with an interhemispheric approach (mean:
570.9 ml, SD: 442) [47]. The mean hospital length of stay for
eTSA ranged from 11 to 13.5 days in two studies [9, 13]
compared to 8.5 to 18 days for mTCA [7, 22, 24, 78]. Of these
studies, one described the mean length of stay in both ap-
proaches, with a mean length of stay of 11 days for eTSA
compared to 8.5 days in mTCA (p = 0.54) [22]. Operating
time ranged from 6 to 10 h in one study reporting outcomes
from eTSA [24]. In a study examining patients with an
interhemispheric approach, the mean operating time was
209 min (standard deviation: 103) [47].
Discussion
In this meta-analysis, eTSA was not shown to be superior to
mTCA for resection of both OGMs and TSMs. Only in pa-
tients with preoperative visual deficits due to TSM, eTSA
seems superior to mTCA, but with great hetereogeneity. In
patients with TSM, eTSA resulted in higher rates of visual
improvement, similar rates of GTR, and more CSF leaks and
intraoperative arterial injury, while in patients with OGM,
results of both techniques were similar for visual improvement
and intraoperative arterial injury, but worse in patients operat-
ed with eTSA for GTR and CSF leaks. There seems to be no
substantial difference in perioperative blood loss, operating
time, or length of hospital stay between the two approaches.
There was no substantial difference between incidence rates in
the fixed- and random-effect models. This could be explained
by a relative lack of difference between the study populations
in the studies, which could have been implicated in the case of
a difference between the models. However, mTCAwas asso-
ciated with considerable heterogeneity for outcomes visual
improvement in TSMs and CSF leak for OGMs, which could
reflect a relatively greater inter-study variability for these
outcomes.
Although no significant difference was identified in GTR
rate for TSM, mTCA resulted in higher GTR rates in OGM.
As OGMs are located more anteriorly than TSM, an extended
eTSA approach is needed for OGM, which requires more
extensive drilling of the anterior skull base and a potential
suboptimal view because of the angle of the scope.
However, it should also be noted that GTR was not always
the primary the goal of surgery (e.g., the goal could be pre-
serving vision) [43, 72]. Furthermore, many other factors
seem to influence GTR rate. One factor may be the learning
curve associated with eTSA, as seen with pituitary adenoma
resection [10, 14, 46]. Also, tumor factors such as large size
and vascular enhancement can significantly lower the GTR
rate for eTSA, as seen in one study in TSM [43].
Furthermore, presence of a Bcortical cuff^ (a layer of brain
between the tumor capsule and cerebral vessels) on MRI
was associated with more GTR in OGM [40].
For visual improvement, it remains to be determined
whether eTSA is truly associated with more visual improve-
ment than mTCA in TSM as correction for the heterogeneity
among mTCA studies could not be done. Therefore, the dif-
ference witnessed may be insignificant as seen with OGM.
Furthermore, as the variance in reporting of tumor size did
not allow for it to be incorporated in a meta-regression, the
TSMs in the eTSA group may be smaller compared to the
mTCA group. However, regarding visual outcomes, one study
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Model Group by
SURGERY
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
0.690.030.20Bohman et al. ETSSeTSA
0.690.030.20Bowers et al ETSSeTSA
0.260.000.02Ceylan et al ETSSeTSA
0.630.020.17Chowdhury et al. EeTSA
0.730.010.13cooket al. ETSSeTSA
0.670.070.29De Devitiis et al. EeTSA
0.560.110.29Fatemi et al. ETSSeTSA
0.690.030.20Gadgil et al. ETSSeTSA
0.470.000.05Hayhurst et al. ETSSeTSA
0.320.030.10Khan et al. ETSSeTSA
0.360.170.25Koutourousiou et al. EeTSA
0.290.010.05Ogawa et al. ETSSeTSA
0.730.010.13Padhye et al. ETSSeTSA
0.410.010.08Wang et al. ETSSeTSA
0.310.000.03Wilk et al. ETSSeTSA
0.260.140.19eTSAFixed
0.260.140.19eTSARandom
mTCA Ali et al. 0.07 0.02 0.23
mTCA Bassiouni et al. 0.01 0.00 0.11
mTCA Bowers et al 0.02 0.00 0.27
mTCA Chokyu et al. 0.01 0.00 0.19
mTCA Curey et al. 0.02 0.00 0.29
mTCA De Devitiis et al. 0.07 0.02 0.19
mTCA Della puppa et al. 0.04 0.01 0.25
mTCA Fatemi et al. 0.05 0.00 0.47
mTCA Ganna et al. 0.02 0.00 0.25
mTCA Landeiro et al. 0.09 0.02 0.29
mTCA Li-Hua et al. 0.01 0.00 0.10
mTCA Mahmoud et al. 0.07 0.03 0.17
mTCA Margalit et al. 0.04 0.01 0.14
mTCA Mathiesen et al. 0.07 0.02 0.24
mTCA Nakamura et al. 0.04 0.01 0.12
mTCA Nanda et al. 0.02 0.00 0.25
mTCA Palani et al. 0.05 0.01 0.18
mTCA Pamir et al. 0.10 0.04 0.23
mTCA Refaat et al. 0.06 0.01 0.34
mTCA Romani et al. 0.06 0.02 0.16
mTCA Schick et al. 0.11 0.05 0.23
mTCA Terasaka et al. 0.11 0.02 0.50
mTCA Wilk et al. 0.03 0.00 0.31
mTCA Zhou et al. 0.04 0.01 0.13
0.080.040.06mTCAFixed
0.080.040.06mTCARandom
0.120.080.10OverallFixed
0.120.080.10OverallRandom
-1.00 -0.50 0.00 0.50 1.00
Model Group by
SURGERY
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
0.350.170.25Fixed
0.350.100.20Random
eTSA Banu et al. E 0.17 0.02 0.63
eTSA De Almeida et al. E 0.30 0.10 0.62
eTSA DeDevitiis et al. E 0.25 0.03 0.76
eTSA Hayhurst et al. E 0.05 0.00 0.47
eTSA Khan et al. E 0.07 0.01 0.35
eTSA Koutourousiou et al. E 0.30 0.19 0.44
eTSA Padhye et al. E 0.38 0.13 0.72
eTSA Tuna et al. 0.02 0.00 0.24
eTSA
eTSA
mTCA Aguiar et al. 0.24 0.10 0.46
mTCA Bassiouni et al. 0.01 0.00 0.11
mTCA Bitter et al. 0.03 0.01 0.12
mTCA Ciurea et al. 0.12 0.06 0.23
mTCA Colli et al. 0.03 0.00 0.32
mTCA De Almeida et al. 0.20 0.05 0.54
mTCA Della Puppa et al. 0.02 0.00 0.29
mTCA Jang et al. 0.05 0.01 0.18
mTCA Mukherjee et al. 0.21 0.10 0.38
mTCA Nakamura et al. 0.02 0.01 0.09
mTCA Nanda et al. 0.04 0.01 0.13
mTCA Pallini et al. 0.04 0.01 0.09
mTCA Pepper et al. 0.16 0.05 0.39
mTCA Refaat et al. 0.36 0.16 0.62
mTCA Romani et al. 0.09 0.04 0.19
mTCA Slavik et al. 0.07 0.02 0.24
mTCA Spektor et al. 0.13 0.07 0.22
0.130.080.11mTCAFixed
0.140.060.09mTCARandom
0.160.110.13OverallFixed
0.160.080.11OverallRandom
-1.00 -0.50 0.00 0.50 1.00
a
b
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looking at the mTCA approach suggests that visual outcomes
are associated with age and duration of visual symptoms but
not with actual tumor size [28].
For both OGM and TSM, eTSA was significantly associ-
ated with more CSF leakage. However, prophylactic lumbar
drain placement varied greatly; in some studies, almost all
patients were given a prophylactic preoperative lumbar drain,
while in other studies none of the included patients were
drained [8, 24, 30, 35, 40, 44]. Also, the different studies used
different reconstruction techniques (e.g., introduction of a
vascularized flap and use of certain glues), although this
caused no considerable heterogeneity among the studies [40,
44, 62]. Another factor in the postoperative CSF leakage rate
may be the neurosurgeon’s level experience. Although the
difference was not significant, in a small number of patients,
one group had two leaks in their first group of patients (n = 8)
compared to none in the latter group (n = 12) [40]. Also, use of
a vascularized flap for reconstruction of the skull base seems
to bring the CSF leakage rate down considerably [40, 43, 62].
Still, this rate is considerably higher than the overall incidence
calculated for mTCA. Further improvement with more sophis-
ticated reconstruction techniques following eTSA may bring
the rate of CSF leakage down to those reported for mTCA.
MTCA for TSM resulted in a significantly lower rate of
intraoperative arterial injury compared to eTSA. However,
this seems not to have caused a significant difference in mor-
tality. Nevertheless, the relatively low number of patients
Model Group by
SURGERY
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit p-Value
eTSA Bohman et al. E 0.08 0.01 0.62 0.10
eTSA Bowers et al ETSS 0.08 0.01 0.62 0.10
eTSA Chowdhury et al. E 0.07 0.00 0.58 0.08
eTSA DeDevitiis et al. E 0.06 0.00 0.54 0.06
eTSA Fatemi et al. ETSS 0.03 0.00 0.37 0.02
eTSA Gadgil et al. ETSS 0.08 0.01 0.62 0.10
eTSA Hayhurst et al. ETSS 0.11 0.02 0.50 0.05
eTSA Khan et al. ETSS 0.02 0.00 0.29 0.01
eTSA Koutourousiou et al. E 0.01 0.00 0.09 0.00
eTSA Ogawa et al. ETSS 0.03 0.00 0.30 0.01
eTSA Padhye et al. ETSS 0.13 0.01 0.73 0.20
eTSA Wang et al. ETSS 0.04 0.00 0.40 0.03
0.000.100.020.05eTSAFixed
0.000.100.020.05eTSARandom
0.000.200.000.03Ali et al.mTCA
mTCA Bassiouni et al. 0.02 0.00 0.11 0.00
mTCA Bowers et al 0.02 0.00 0.27 0.01
mTCA Ceylan et al 0.02 0.00 0.26 0.01
mTCA Chokyu et al. 0.01 0.00 0.19 0.00
mTCA Curey et al. 0.02 0.00 0.29 0.01
mTCA De Devitiis et al. 0.01 0.00 0.15 0.00
mTCA Della puppa et al. 0.02 0.00 0.26 0.01
mTCA Fatemiet al. 0.11 0.02 0.50 0.05
0.000.150.000.02Li et al.
mTCA Gannaet al. 0.02 0.00 0.25 0.01
mTCA Jang et al. 0.02 0.00 0.25 0.01
mTCA Landeiro et al. 0.02 0.00 0.26 0.01
mTCA
mTCA Li-Hua et al. 0.01 0.00 0.11 0.00
mTCA Mahmoud et al. 0.01 0.00 0.12 0.00
mTCA Margalit et al. 0.01 0.00 0.14 0.00
mTCA Mathiesen et al. 0.02 0.00 0.22 0.00
mTCA Nakamura et al. 0.01 0.00 0.10 0.00
0.000.030.010.02Fixed
0.000.030.010.02
mTCA Nanda et al. 0.02 0.00 0.25 0.01
mTCA Palani et al. 0.01 0.00 0.16 0.00
mTCA Pamir e tal. 0.01 0.00 0.16 0.00
mTCA Refaat et al. 0.03 0.00 0.34 0.01
mTCA Romani et al. 0.01 0.00 0.13 0.00
mTCA Schick et al. 0.01 0.00 0.13 0.00
mTCA Terasaka et al. 0.05 0.00 0.47 0.04
mTCA Wilk et al. 0.03 0.00 0.31 0.01
mTCA Zhou et al. 0.01 0.00 0.13 0.00
mTCA
mTCARandom
0.000.040.020.03OverallFixed
0.000.040.020.03OverallRandom
-1.00 -0.50 0.00 0.50 1.00
Fig. 4 Pooled prevalence rates of intraoperative arterial injury by
approach for tuberculum sellae meningioma resection: endoscopic
transsphenoidal approach vs. microscopic transcranial approach. P-
interaction value: 0.03. eTSA, endoscopic transsphenoidal approach;
mTCA, microscopic transcranial approach
Fig. 3 a Pooled prevalence of cerebrospinal fluid leak by approach for
tuberculum sellae meningioma resection: endoscopic transsphenoidal
approach vs. microscopic transcranial approach. P-interaction value <
0.01. CSF, cerebrospinal fluid; eTSA, endoscopic transsphenoidal ap-
proach; mTCA, microscopic transcranial approach. b Pooled prevalence
rates of cerebrospinal fluid leak by approach for olfactory groove menin-
gioma resection: endoscopic transsphenoidal approach vs. microscopic
transcranial approach. P-interaction value < 0.01; CSF, cerebrospinal flu-
id; eTSA, endoscopic transsphenoidal approach; mTCA, microscopic
transcranial approach
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treated with an eTSAmay have caused a relatively low power,
as the p-interaction value for mortality for TSM approaches
significance (p = 0.14). A significant association between in-
traoperative arterial injury and eTSA was not seen in OGM;
again, this may be explained by low power and the small
number of studies, but also because of the anterior location
of the tumor.
Previously, two reviews have described a comparison be-
tween eTSA and mTCA for both TSM and OGM. The first
review identified a higher GTR rate and less CSF leakage
associated with mTCA for both OGM and TSM (p < 0.01
for both, using the chi-squared test and Fisher’s exact test,
respectively), which is similar to our findings except for the
GTR rate for TSM [42]. A second review found significantly
more visual improvement (p < 0.01) and CSF leakage
(p < 0.01) for eTSA and no difference in mortality
(p = 0.15) for TSM andOGM together, similar to our findings.
eTSAwas also found to be associated with a lower GTR rate
(p < 0.01) compared to mTCA, which was only the case in
OGM in this meta-analysis [71]. Finally, the authors of a meta-
analysis for TSM found that eTSAwas significantly associat-
ed with CSF leakage (OR: 3.9; 95% CI: 1.15–15.75, p < 0.05)
and visual improvement (OR 1.5; 95% CI 1.18, 1.82,
p < 0.05), which again is similar to our results [18].
Strengths of this study include an extensive review of the
literature and evaluation of outcomes such as arterial injury,
length of hospital stay, and blood loss. The use of both fixed-
and random-effect models, evaluation of heterogeneity be-
tween the included studies, and assessment of publication bias
ensures a rigorous evaluation of outcomes with appropriate
valuation of the results. All outcomes were also subjected to
meta-regression for various study characteristics where possi-
ble to try to identify sources of heterogeneity between the
studies.
There are several limitations of this meta-analysis. First, the
decision to discard studies published before 2004 produces a
limitation. The decision to do so was based on the assumption
that also mTCA outcomes improve over time with continual
innovation and that meningiomas were not reported to be
resected with an eTSA before that time [26, 38]. Regarding
the included studies, only case series were identified, resulting
in the inability of calculation overall odds ratios. There is
probably also a great difference between the population of
patients who were deemed eligible for an eTSA resection
compared to those resected with mTCA because of the size,
extension, and invasion of the tumors (confounding by indi-
cation). Furthermore, one could argue that only looking at
perioperative outcomes may not be conclusive as especially
recurrence happens during follow-up. However, as the GTR
and World Health Organization (WHO) grade remain the
main prognostic factors for predicting recurrence, opting for
eTSA should be done with great caution as high-grade menin-
giomas may be harder to resect completely [59, 74]. However,
it was not possible to correct for meningioma size, which is
unfortunate as very small meningiomas may show very dif-
ferent results. Furthermore, it was not possible to correct for
WHO grade, which could theoretically alter the results [31].
Also, the choice of approach varied greatly among mTCA
approach studies [1, 2, 5–7, 9, 47, 51, 56, 64, 70].
Indications for eTSA vary between groups. One group re-
ported operating on all midline meningiomas regardless of
size, extension, or configuration except for those tumors that
extend from the anterior clinoid process [43]. It has also been
suggested that if the tumor extends laterally over the internal
carotid artery, chances of GTR are limited [61]. Others have
suggested that larger tumors, tumors that extend laterally, in-
volve vasculature, or are calcified are also lesser candidates
[23, 44]. Therefore, confounding by indication cannot be
ruled out, especially since the patients in these studies were
not randomized to either treatment. As a result, the exact in-
dications and contraindications for eTSA remain to be
determined.
Future studies should, therefore, focus on identifying clear
indications for eTSA for OGM and TSM and its safety by
direct comparison in a randomized study. Such a study should
ideally be conducted in a research setting by experienced sur-
geons, as its safety has not been prospectively compared to
mTCA and as both approaches seem to come with a consid-
erable learning curve, which results in different outcomes
[43]. Given the observation that younger patients seem to
benefit more from eTSA compared to older patients
(p = 0.02, n = 34), it is not unlikely that specific groups might
benefit more from one of the approaches [39]. Probably, pa-
tients with relatively small (<3 cm) midline TSMs would
probably be the best early candidates. These patients may
benefit from a potential higher incidence of visual improve-
ment postoperatively and the relative invasiveness of the
eTSA approach. Further evaluation could be focused on char-
acteristics such as size, a cortical cuff, and WHO grading to
identify the best potential candidates for either approach [40].
However, due to the low incidence of TSMs and OGMs in
general and the great variety in anatomical characteristics
among them, this may be challenging. Therefore, other trial
designs—e.g., a registry—should be considered when an-
swering this question. Also, future improvement of the instru-
ments used (e.g., 3D endoscopes or glues) may improve the
results obtained by eTSA over time [33].
Conclusion
This meta-analysis indicates that the endoscopic
transsphenoidal approach (eTSA) has not been shown to be
superior to the microscopic transsphenoidal approach
(mTCA) for either olfactory groove meningiomas (OGMs)
or tuberculum sellae menigniomas (TSMs). More specifically,
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eTSA was associated with lower GTR rate for OGMs and
higher rate of arterial injury for TSMs compared to mTCA.
Furthermore, eTSA was associated with more CSF leaks in
both OGMs and TSMs compared to mTCA. On the other
hand, eTSA was associated with a higher rate of visual im-
provement postoperatively compared to mTCA in TSMs,
which was not observed for OGMs. All conclusions should,
however, be interpreted with caution because of the limita-
tions of this study.
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